CD33 and myelodysplastic syndrome: Treatment with CD16 × CD33 BiKE enhances degranulation and tumor necrosis factor (TNF)-α, and interferon (IFN)-γ production against CD33+ myelodysplastic syndrome targets and reverses immunosuppression of NK cells by myeloid-derived suppressive cells15.